2 research outputs found
Usporedba 18F-FDG pozitronske emisijske tomografije i kompjutorizirane tomografije u bolesnika s kolorektalnim karcinomom i limfomom: naÅ”a poÄetna kliniÄka iskustva
Findings obtained by fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG PET) and computed tomography (CT) were compared in patients with malignant lymphoma and colorectal carcinoma. In 14 malignant lymphoma patients, 16 18F-FDG PET procedures were performed to assess chemotherapy and/or radiotherapy outcome (remission). One patient with clinically overt relapse of non-Hodgkin.s lymphoma underwent PET to assess disease dissemination prior to prescribing second-line chemotherapy. Two patients were submitted to PET on two occasions. PET pointed to residual disease in six of 14 patients and was inconclusive in one patient. These patients underwent computed tomography (CT), some of them before and others after PET examination. Then PET and CT findings were compared and therapeutic response, i.e. disease remission was assessed. The signs of residual disease were present in four and absent in nine patients, whereas inconclusive findings in terms of residual disease were recorded in one patient. Although our initial clinical experience was acquired in quite a small number of patients, CT modified clinical evaluation of residual disease in two patients and should be included along with PET in diagnostic work-up of these patients.Usporedili smo nalaze fluoro-18-fluorodeoksiglukoza (FDG) pozitronske emisijske tomografije (18F-FDG PET) i kompjutorizirane tomografije (CT) u bolesnika s malignim limfomom i kolorektalnim karcinom. U 14 bolesnika 18F-FDG PET je uÄinjen 16 puta radi procjene ishoda kemoterapije i/ili radioterapije, odnosno remisije. U jednog bolesnika s kliniÄki jasnim recidivom ne-Hodgkinova limfoma PET je proveden radi procjene proÅ”irenosti bolesti prije ordiniranja druge linije kemoterapije. U dvoje bolesnika PET je uÄinjena dva puta. U Å”estoro od 14 bolesnika nalaz PET ukazivao je na rezidualnu bolest, dok je u jednog bolesnika bio dvojben. Stoga je u tih bolesnika uÄinjena i CT; u nekih bolesnika CT je izvedena prije PET, a u drugih nakon PET. Tada smo usporedili nalaze PET i CT te procijenili terapijski odgovor, tj . remisiju bolesti. Znaci rezidualne bolesti bili su prisutni u Äetvoro bolesnika, odsutni u devetoro bolesnika, dok je kod jednog bolesnika i dalje bilo nejasno je li rezidualna bolest prisutna ili nije. Iako se ovo naÅ”e poÄetno kliniÄko iskustvo odnosi na mali broj bolesnika, CT je promijenio kliniÄku procjenu rezidualne bolesti u dvoje bolesnika i smatramo da bi uz PET i CT trebao biti sastavni dio dijagnostiÄke obrade takvih bolesnika
Usporedba 18F-FDG pozitronske emisijske tomografije i kompjutorizirane tomografije u bolesnika s kolorektalnim karcinomom i limfomom: naÅ”a poÄetna kliniÄka iskustva
Findings obtained by fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG PET) and computed tomography (CT) were compared in patients with malignant lymphoma and colorectal carcinoma. In 14 malignant lymphoma patients, 16 18F-FDG PET procedures were performed to assess chemotherapy and/or radiotherapy outcome (remission). One patient with clinically overt relapse of non-Hodgkin.s lymphoma underwent PET to assess disease dissemination prior to prescribing second-line chemotherapy. Two patients were submitted to PET on two occasions. PET pointed to residual disease in six of 14 patients and was inconclusive in one patient. These patients underwent computed tomography (CT), some of them before and others after PET examination. Then PET and CT findings were compared and therapeutic response, i.e. disease remission was assessed. The signs of residual disease were present in four and absent in nine patients, whereas inconclusive findings in terms of residual disease were recorded in one patient. Although our initial clinical experience was acquired in quite a small number of patients, CT modified clinical evaluation of residual disease in two patients and should be included along with PET in diagnostic work-up of these patients.Usporedili smo nalaze fluoro-18-fluorodeoksiglukoza (FDG) pozitronske emisijske tomografije (18F-FDG PET) i kompjutorizirane tomografije (CT) u bolesnika s malignim limfomom i kolorektalnim karcinom. U 14 bolesnika 18F-FDG PET je uÄinjen 16 puta radi procjene ishoda kemoterapije i/ili radioterapije, odnosno remisije. U jednog bolesnika s kliniÄki jasnim recidivom ne-Hodgkinova limfoma PET je proveden radi procjene proÅ”irenosti bolesti prije ordiniranja druge linije kemoterapije. U dvoje bolesnika PET je uÄinjena dva puta. U Å”estoro od 14 bolesnika nalaz PET ukazivao je na rezidualnu bolest, dok je u jednog bolesnika bio dvojben. Stoga je u tih bolesnika uÄinjena i CT; u nekih bolesnika CT je izvedena prije PET, a u drugih nakon PET. Tada smo usporedili nalaze PET i CT te procijenili terapijski odgovor, tj . remisiju bolesti. Znaci rezidualne bolesti bili su prisutni u Äetvoro bolesnika, odsutni u devetoro bolesnika, dok je kod jednog bolesnika i dalje bilo nejasno je li rezidualna bolest prisutna ili nije. Iako se ovo naÅ”e poÄetno kliniÄko iskustvo odnosi na mali broj bolesnika, CT je promijenio kliniÄku procjenu rezidualne bolesti u dvoje bolesnika i smatramo da bi uz PET i CT trebao biti sastavni dio dijagnostiÄke obrade takvih bolesnika